Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
NGN-9076
- Development stage
- Unknown
- Lead developer
- NeuroGeneration
- Modality
- Stem Cell Therapies → Cell Therapies
- Administration
- Intracerebral
01
Overview
NGN-9076 is an investigational cell therapy consisting of differentiated neurons derived from adult central nervous system progenitor (neural stem) cells, being developed by NeuroGeneration as a restorative treatment for Parkinson’s disease. The product is intended to replace or supplement degenerating nigrostriatal neurons by transplanting neural stem cell-derived neurons into targeted brain regions, with the goal of improving motor function and modifying disease progression rather than only providing symptomatic relief.[3][5] It is being evaluated in clinical studies of neural stem cell-derived neuron transplantation for Parkinson’s disease.[3][9][5]
- Other names
- Neural Stem Cell-derived NeuronsAdult CNS Progenitor-derived NeuronsNeural Stem Cell Transplantation
Beyond the preview
Go deeper on NGN-9076.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on NGN-9076.